noom semaglutide dosing expands its GLP-1 range with 'microdose' package Weight-loss company Noom pivots to

Following this spike, prescribing was relatively stable from September through November (0.01 percentage points per month), before increasing again from November to December (+0.04 points) and accelerating from December 2025 through February 2026 (+0.12 percentage points per month)

This early clinical observation, combined with increased accessibility, is what popularized the strategy of Microdosing GLP-1

The precise escalation regimen for any future approved formulation may differ substantially from trial protocols

Like other GLP-1 medications, compounded semaglutide with glycine is contraindicated for patients with a history of medullary thyroid carcinoma, MEN2 (multiple endocrine neoplasia type 2) syndrome, pancreatitis, and gallbladder issues